Uri Tadelis was appointed as Chief Financial Officer at Raphael Pharmaceutical Inc..
“Effective July 16, 2026, the Company appointed Mr. Uri Tadelis as its Chief Financial Officer.”
Raphael Pharmaceutical Inc. — fact timeline
Source-grounded facts extracted from Raphael Pharmaceutical Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director at Raphael Pharmaceutical Inc..
“Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026.”
Ajay Kumar Dhadha resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..
“Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026.”
Shlomo Pilo changed role as Chairman at Raphael Pharmaceutical Inc..
“The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.”
Ajay Kumar Dhadha was appointed as Director and Chairman at Raphael Pharmaceutical Inc..
“The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.”
Joseph Press resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..
“On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.